PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Agile Therapeutics, Inc. (AGRX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00847L1008
CUSIP00847L100
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic

Highlights

Market Cap$2.57M
EPS-$6.71
PE Ratio0.05
Revenue (TTM)$19.59M
Gross Profit (TTM)-$6.62M
EBITDA (TTM)-$19.50M
Year Range$0.20 - $4.93
Target Price$5.00
Short %7.50%
Short Ratio0.28

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Agile Therapeutics, Inc.

Popular comparisons: AGRX vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Agile Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%December2024FebruaryMarchAprilMay
-100.00%
178.72%
AGRX (Agile Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Agile Therapeutics, Inc. had a return of -79.51% year-to-date (YTD) and -90.89% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-79.51%11.05%
1 month3.60%4.86%
6 months-81.24%17.50%
1 year-90.89%27.37%
5 years (annualized)-83.06%13.14%
10 years (annualized)N/A10.90%

Monthly Returns

The table below presents the monthly returns of AGRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-21.54%-48.04%-57.23%30.88%-79.51%
202318.94%-11.15%-6.63%-42.41%-41.24%-22.16%-1.69%-10.34%-7.69%-24.58%16.57%-7.58%-82.82%
2022-28.50%-12.32%-31.54%-72.67%-38.86%-16.79%-56.15%-21.22%-26.24%-6.03%-24.73%8.10%-98.84%
2021-1.74%1.77%-27.53%-11.06%-12.97%-17.39%-9.77%-3.33%-17.15%-17.45%-20.59%-22.52%-82.99%
202048.00%-27.70%-30.47%30.38%16.29%-1.42%-10.07%28.00%-5.00%-10.53%3.68%1.77%14.80%
201940.65%11.23%67.59%0.66%-17.76%16.80%-20.55%-5.17%7.73%1.27%75.00%19.05%334.10%
201821.93%10.67%-29.20%10.12%-80.21%-11.79%-40.69%-0.00%25.09%129.41%3.15%-33.60%-78.59%
2017-59.65%-3.48%44.37%12.01%-8.64%14.33%26.40%-27.43%29.65%6.50%5.47%-46.31%-52.81%
2016-37.50%-5.57%7.81%-6.76%38.17%-4.88%-8.02%3.43%-3.59%8.88%-9.61%-17.03%-41.60%
201541.69%24.60%-14.48%25.35%-18.59%-9.20%6.29%-3.29%-23.67%17.80%12.34%9.42%58.96%
20145.60%49.06%-28.33%35.04%-13.51%-2.74%-16.20%3.19%10.83%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AGRX is 4, indicating that it is in the bottom 4% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of AGRX is 44
AGRX (Agile Therapeutics, Inc.)
The Sharpe Ratio Rank of AGRX is 77Sharpe Ratio Rank
The Sortino Ratio Rank of AGRX is 11Sortino Ratio Rank
The Omega Ratio Rank of AGRX is 33Omega Ratio Rank
The Calmar Ratio Rank of AGRX is 33Calmar Ratio Rank
The Martin Ratio Rank of AGRX is 55Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Agile Therapeutics, Inc. (AGRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


AGRX
Sharpe ratio
The chart of Sharpe ratio for AGRX, currently valued at -0.86, compared to the broader market-2.00-1.000.001.002.003.004.00-0.86
Sortino ratio
The chart of Sortino ratio for AGRX, currently valued at -2.27, compared to the broader market-4.00-2.000.002.004.006.00-2.27
Omega ratio
The chart of Omega ratio for AGRX, currently valued at 0.72, compared to the broader market0.501.001.502.000.72
Calmar ratio
The chart of Calmar ratio for AGRX, currently valued at -0.91, compared to the broader market0.002.004.006.00-0.91
Martin ratio
The chart of Martin ratio for AGRX, currently valued at -1.48, compared to the broader market-10.000.0010.0020.0030.00-1.48
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.49, compared to the broader market-2.00-1.000.001.002.003.004.002.49
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.52, compared to the broader market-4.00-2.000.002.004.006.003.52
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.43, compared to the broader market0.501.001.502.001.43
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 2.03, compared to the broader market0.002.004.006.002.03
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 9.57, compared to the broader market-10.000.0010.0020.0030.009.57

Sharpe Ratio

The current Agile Therapeutics, Inc. Sharpe ratio is -0.86. This value is calculated based on the past 12 months of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Agile Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2024FebruaryMarchAprilMay
-0.86
2.49
AGRX (Agile Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Agile Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2024FebruaryMarchAprilMay
-100.00%
-0.21%
AGRX (Agile Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Agile Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Agile Therapeutics, Inc. was 100.00%, occurring on Apr 1, 2024. The portfolio has not yet recovered.

The current Agile Therapeutics, Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Apr 17, 20152254Apr 1, 2024
-45.35%Jun 25, 2014122Dec 16, 201449Feb 27, 2015171
-20.5%Mar 5, 201515Mar 25, 20158Apr 7, 201523
-9.22%Jun 4, 20142Jun 5, 20144Jun 11, 20146
-3.04%Jun 20, 20141Jun 20, 20141Jun 23, 20142

Volatility

Volatility Chart

The current Agile Therapeutics, Inc. volatility is 22.17%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%December2024FebruaryMarchAprilMay
22.17%
3.40%
AGRX (Agile Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Agile Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items